Published in Clin Cancer Res on June 01, 2005
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs. J Vet Intern Med (2015) 2.58
Nanotechnology and cancer. Annu Rev Med (2008) 2.25
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine (2009) 1.93
Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol (2010) 1.90
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale (2011) 1.25
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine (2009) 1.25
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther (2011) 1.04
Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol (2009) 1.01
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol (2014) 1.00
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol (2009) 0.99
First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. Int J Nanomedicine (2013) 0.98
Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem (2014) 0.93
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci (2014) 0.92
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J (2009) 0.90
Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PLoS One (2015) 0.89
Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials (2012) 0.89
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther (2015) 0.88
Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia (2008) 0.87
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol (2010) 0.85
Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical Translation. Nano Today (2015) 0.83
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther (2015) 0.83
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs (2008) 0.82
Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers (Basel) (2011) 0.81
A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials (2016) 0.80
Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions. Nanoscale (2016) 0.78
Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol (2011) 0.78
Folate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimental murine H22 metastasis models. Int J Nanomedicine (2014) 0.78
PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery. J Control Release (2015) 0.78
A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. J Radiat Res (2015) 0.77
Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage. Int J Nanomedicine (2016) 0.77
A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity. Sci Rep (2016) 0.77
DNA nanotechnology: a future perspective. Nanoscale Res Lett (2013) 0.77
A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery. J Pharm Sci (2012) 0.76
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines. Invest New Drugs (2015) 0.76
A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. Int J Med Sci (2014) 0.76
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Br J Cancer (2015) 0.76
When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics? Drug Metab Dispos (2016) 0.75
Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1). Int J Nanomedicine (2017) 0.75
2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model. Int J Nanomedicine (2014) 0.75
Management of carcinoma in situ of the bladder: best practice and recent developments. Ther Adv Urol (2015) 0.75
Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy. Oncotarget (2017) 0.75
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer (2016) 0.75
Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther (2009) 0.75
Comparative Cytotoxic Evaluation of Free and Sodium Alginate Nanoparticle-Encapsulated ICD-85 on Primary Lamb Kidney Cells. Iran J Cancer Prev (2013) 0.75
Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Oncol Lett (2017) 0.75
The use of nanoparticulates to treat breast cancer. Nanomedicine (Lond) (2017) 0.75
Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization. Int J Nanomedicine (2017) 0.75
Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel. Front Immunol (2017) 0.75
Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes. Int J Pharm (2017) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Pharmacy education: back to the basics? Pharmacotherapy (2003) 4.11
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Posttraumatic stress disorder in survivors of acute lung injury: evaluating the Impact of Event Scale-Revised. Chest (2013) 3.00
A comparison of the abilities of nine scoring algorithms in predicting mortality. J Trauma (2002) 2.70
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Thalidomide. Lancet (2004) 2.21
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev (2008) 2.06
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs (2008) 2.01
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol (2009) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A (2009) 1.89
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol (2004) 1.73
Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res (2008) 1.73
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol (2002) 1.71
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol (2005) 1.70
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol (2002) 1.68
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Drug interactions in cancer therapy. Nat Rev Cancer (2006) 1.62
Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol (2003) 1.61
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res (2006) 1.60
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther (2010) 1.58
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat (2003) 1.54
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res (2004) 1.52
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol Ther (2002) 1.50
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol (2007) 1.46
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem (2009) 1.44
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther (2007) 1.40
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res (2006) 1.40
2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy (2003) 1.40
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal (2008) 1.39
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res (2002) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem (2010) 1.36
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies. Ann Pharmacother (2004) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One (2011) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation (2002) 1.29
Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 1.29
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol (2005) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol (2003) 1.26
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res (2004) 1.25
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.25
Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro (2005) 1.24
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res (2002) 1.23